AntriaBio, Inc. (ANTB.OB) is another still-developing player in the sector of diabetes treatment that has recently pulled back and could be worth a look to both short- and long-term investors. This company is bringing to human trials over the near term a once-a-week basal insulin shot (AB101) that would look to replace the once-daily current standard of care. The noted benefits to a patient's quality of life that this product could have to those currently needing a shot a day is obvious, and AntriaBio shares have the potential to move in-line with catalysts as they develop during the coming quarters - especially in light of the recent pullback. After hitting highs of over two roughly a month ago, the share price has trickled lower on light volume, an indication that those who are already in are holding, while others looking to get in may do so when the see the share price settle. Given the relatively light volume, however, this one could still be trading below the radar - but that could change as progress is made this year in the clinical development of AB101.
Human trials in Russia are slated to begin over the near term and once data starts rolling in from those trials, then AntriaBio plans to use that data - assuming its positive - to search for potential partners, whether they be regional or international, according to a recent presentation (pdf). Diabetes is growing at a very rapid pace worldwide, as discussed in the SanuWave write-up, so AntriaBio could be positioning to enter a very lucrative market and could attract the swift interest of partners or potential acquirers if human trials move forward with success.
In addition to the above-mentioned catalyst events, FDA milestones could be forthcoming, as well, as the company has stated plans to proceed with the IND process in the U.S. while simultaneously conducting trials overseas. Emphasis has been put on the overseas trials first, however, due to significant costs benefits of conducting trials elsewhere, while patient recruitment is often easier, too. Once some human data is established, then it makes the FDA process at home a little bit easier. The path to approval should also be estimated as quicker than the standard drug approval process, due to the established nature of basal insulin, meaning developments could unfold quickly once trials are started.
Standard risks apply for developmental companies in the sector, but the recent price pullback, pending catalysts and overall potential of AB101 in the commercial market - should it make it that far - makes AntriaBio's recent trading action worth watching.
http://seekingalpha.com/article/1298501-weekly-stock-watch-week-of-march-25?source=yahoo
Recent RZLT News
- Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting • GlobeNewswire Inc. • 04/23/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 09:03:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2024 02:35:50 PM
- Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH) • GlobeNewswire Inc. • 03/06/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 01:47:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 10:00:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 04:55:02 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 10:00:07 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/13/2024 09:20:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 09:10:54 PM
- Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update • GlobeNewswire Inc. • 02/13/2024 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/29/2024 10:15:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 05:36:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 05:10:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 05:06:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 05:04:28 PM
- Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer • GlobeNewswire Inc. • 01/24/2024 01:00:00 PM
- Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism • GlobeNewswire Inc. • 01/23/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/14/2023 09:01:36 PM
- Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism • GlobeNewswire Inc. • 12/14/2023 01:00:00 PM
- Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”) • GlobeNewswire Inc. • 12/13/2023 01:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/30/2023 05:15:07 AM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 11/22/2023 10:16:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/22/2023 09:35:47 PM
- Rezolute to Participate in BTIG’s 3rd Annual Ophthalmology Day • GlobeNewswire Inc. • 11/17/2023 01:00:00 PM
FEATURED Element79 Gold Corp Reports Exceptionally High-Grade Results from Lucero • May 14, 2024 7:00 AM
VAYK Added New Manager for Expansion into $64 Billion Domestic Short-term Rental Market • VAYK • May 14, 2024 9:00 AM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM